Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ablynx Receives Milestone Payment as Collaborator Receives IND Approval for a Nanobody in Oncology

Published: Friday, April 06, 2012
Last Updated: Friday, April 06, 2012
Bookmark and Share
Company has received a €400,000 milestone payment from its collaboration with Novartis.

Ablynx has announced that it has received a €400,000 milestone payment from its collaboration with Novartis.

The payment was triggered by the approval of an Investigational New Drug (IND) application from the U.S. Food and Drug Administration for the Phase 1 clinical trial for a Nanobody® licensed to Novartis.

This is the first development candidate emerging from the licensing agreement between Ablynx and Novartis.

Ablynx and Novartis entered into a commercial licensing agreement in July 2010, under which Novartis obtained licenses to develop and commercialize Nanobodies against two targets (including this one for which an IND has been approved), which originated from the research agreement between the parties, entered into in 2005.

Since July 2010, Novartis has full responsibility for the continued progress of both programmes and Ablynx is eligible to receive development-based milestone payments and royalties on sales following commercialization of the products.

Dr Edwin Moses, CEO and Chairman of Ablynx, commented: “We are excited that Novartis has obtained IND approval and that they will bring this first Nanobody into clinical development in an oncology setting. This development candidate demonstrates the power of the Nanobody platform in addressing complex target classes that are challenging to address with conventional antibodies.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genzyme to Collaborate with Ablynx on MS Research Project
Research collaboration to investigate Nanobodies® against a target that plays an important role in multiple sclerosis.
Friday, May 22, 2015
Ablynx Initiates Phase I Study With ALX-0171 for the Treatment of Respiratory Syncytial Virus (RSV)
The company announced it has initiated a Phase I study in healthy volunteers with ALX- 0171, the first Nanobody in clinical development to be delivered by inhalation.
Tuesday, December 13, 2011
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!